SNX-5422 MESYLATE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C25H30F3N5O4.CH4O3S
Molecular Weight	617.638
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CS(O)(=O)=O.CC1(C)CC2=C(C(=NN2C3=CC(N[C@H]4CC[C@@H](CC4)OC(=O)CN)=C(C=C3)C(N)=O)C(F)(F)F)C(=O)C1

InChI

InChIKey=NVGFSTMGRRADRG-IOJSEOPQSA-N

InChI=1S/C25H30F3N5O4.CH4O3S/c1-24(2)10-18-21(19(34)11-24)22(25(26,27)28)32-33(18)14-5-8-16(23(30)36)17(9-14)31-13-3-6-15(7-4-13)37-20(35)12-29;1-5(2,3)4/h5,8-9,13,15,31H,3-4,6-7,10-12,29H2,1-2H3,(H2,30,36);1H3,(H,2,3,4)/t13-,15-;

HIDE SMILES / InChI

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C25H30F3N5O4
Molecular Weight	521.532
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18172276 | https://www.ncbi.nlm.nih.gov/pubmed/24582562 | https://www.ncbi.nlm.nih.gov/pubmed/25334086

SNX-2112, a novel 2-aminobenzamide inhibitor of heat shock protein 90 (Hsp90) was discovered by Serenex. This drug was investigated for treatment of different cancer cell lines, including hepatocellular carcinoma cells, breast cancer cells and in combination with 5-fluorouracil in esophageal cancer. However, subsequent development has been discontinued due to ocular toxicity as identified in a phase I study.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Heat shock protein HSP90 35 Target ID: CHEMBL2095165 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18172276	Inhibitor 8504		30.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Breast cancer 432 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21821931	Primary	Basic research	Unknown Approved Use Unknown
Esophageal cancer 12 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25333998	Primary	Basic research	Unknown Approved Use Unknown
Hepatocellular carcinoma 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24582562	Primary	Basic research	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.	2011-01-01	21208906
Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.	2009	20225761
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.	2008-01-01	18172276

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Treatment of BT-474 cells with 1 μM SNX-2112 results in down-regulation of HER2 expression. Treatment with SNX-2112 also results in a decline in total Akt expression. SNX-2112 inhibits cell proliferation with IC50 values ranging from 10 to 50 nM, in BT474, SKBR-3, SKOV-3, MDA-468, MCF-7 and H1650 cancer cells. And these antiproliferative effects are associated with hypophosphorylation of Rb, arrest of G1 and modest levels of apotosis.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 20:52:59 GMT 2025` Edited by `admin` on `Mon Mar 31 20:52:59 GMT 2025`
Record UNII	K3BO8V06RM
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SNX-5422 MESYLATE

Common Name

English

GLYCINE, TRANS-4-((2-(AMINOCARBONYL)-5-(4,5,6,7-TETRAHYDRO-6,6-DIMETHYL-4-OXO-3-(TRIFLUOROMETHYL)-1H-INDAZOL-1-YL)PHENYL)AMINO)CYCLOHEXYL ESTER, METHANESULFONATE (1:1)

Preferred Name

English

HSP90 INHIBITOR SNX-5422 MESYLATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C74526